MedTrace Logo

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00162760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2010-06-22

No results posted yet for this study

Summary

The goal of this study is to determine whether thalidomide can stop the progression of fibrosis in IPF.

The primary objective of this study is to determine the safety, feasibility and efficacy of 400 mg of thalidomide administered daily for one year in patients with idiopathic pulmonary fibrosis (IPF) who have failed or are not candidates for treatment with corticosteroids and/or cytotoxic drugs.

The study population will consist of patients with biopsy-proven moderate to severe IPF who have failed or are not candidates for standard therapy with corticosteroids and/or cytotoxic drugs.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

Thalidomide

Sponsors & Collaborators

Principal Investigators

  • Maureen R Horton, M.D. · Johns Hopkins School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162760 on ClinicalTrials.gov